- Home
- TGTX vs SGHC Comparison
TGTX vs SGHC Comparison
Compare TGTX & SGHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- SGHC
- Stock Information
- Founded
- TGTX 1993
- SGHC 2020
- Country
- TGTX United States
- SGHC Guernsey
- Employees
- TGTX N/A
- SGHC N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- SGHC Services-Misc. Amusement & Recreation
- Sector
- TGTX Health Care
- SGHC Consumer Discretionary
- Exchange
- TGTX Nasdaq
- SGHC Nasdaq
- Market Cap
- TGTX 5.1B
- SGHC 6.0B
- IPO Year
- TGTX 1995
- SGHC N/A
- Fundamental
- Price
- TGTX $36.73
- SGHC $13.50
- Analyst Decision
- TGTX Strong Buy
- SGHC Strong Buy
- Analyst Count
- TGTX 6
- SGHC 8
- Target Price
- TGTX $47.50
- SGHC $15.50
- AVG Volume (30 Days)
- TGTX 1.9M
- SGHC 3.7M
- Earning Date
- TGTX 11-03-2025
- SGHC 11-05-2025
- Dividend Yield
- TGTX N/A
- SGHC 1.15%
- EPS Growth
- TGTX N/A
- SGHC 1999.69
- EPS
- TGTX 0.36
- SGHC 0.29
- Revenue
- TGTX $454,069,000.00
- SGHC $2,230,781,944.00
- Revenue This Year
- TGTX $82.22
- SGHC $25.57
- Revenue Next Year
- TGTX $47.76
- SGHC $8.11
- P/E Ratio
- TGTX $101.18
- SGHC $46.93
- Revenue Growth
- TGTX 30.96
- SGHC 37.19
- 52 Week Low
- TGTX $21.16
- SGHC $3.77
- 52 Week High
- TGTX $46.48
- SGHC $14.38
- Technical
- Relative Strength Index (RSI)
- TGTX 72.14
- SGHC 59.07
- Support Level
- TGTX $34.52
- SGHC $12.91
- Resistance Level
- TGTX $37.45
- SGHC $14.38
- Average True Range (ATR)
- TGTX 1.10
- SGHC 0.69
- MACD
- TGTX 0.59
- SGHC 0.10
- Stochastic Oscillator
- TGTX 90.30
- SGHC 69.97
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About SGHC Super Group (SGHC) Limited
Super Group (SGHC) Ltd is a holding company that operates online sports betting and gaming businesses. The company's reportable segments are Betway, Spin, and Other. A majority of its revenue is generated from the Betway segment, which is a single-brand online sports betting and casino offering with licenses to operate throughout Europe, the Americas, and Africa. Spin is the company's multi-brand online casino offering, having a diverse portfolio of casino brands such as Jackpot City, Spin Casino, Dream Bingo, Mirror Bingo, etc., designed to be culturally relevant globally while aiming to offer a wide range of casino products. Geographically, the company generates maximum revenue from Africa and Middle East, followed by North America, Europe, Asia-Pacific, and South/Latin America.